Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
propofol + rocuronium + remifentanil + fentanyl
- Development stage
- Unknown
- Lead developer
- University Hospital Basel
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Propofol + rocuronium + remifentanil + fentanyl is a multi-drug anesthetic combination used as a conventional opioid-based anesthesia protocol. This specific regimen was employed as the control arm in clinical trials conducted by the University Hospital, Basel, to evaluate nociception levels during surgery. The combination provides a comprehensive anesthetic state: propofol acts as a hypnotic agent via GABA-A receptor modulation; rocuronium provides neuromuscular blockade by antagonizing nicotinic acetylcholine receptors; and the synthetic opioids fentanyl and remifentanil provide potent analgesia through mu-opioid receptor activation. This protocol is typically administered intravenously to patients undergoing procedures such as laparoscopic surgery to ensure hypnosis, muscle relaxation, and pain control.
- Other names
- conventional opioid-based groupconventional opioid-based anaesthesia protocolconventional opioid-based group-University Hospital, Basel, Switzerland-surgical pain
02
Targets
GABRR (GABA-A receptor subunit rho)Nicotinic Acetylcholine ReceptorMOR (Mu opioid receptor)
Beyond the preview
Go deeper on propofol + rocuronium + remifentanil + fentanyl.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on propofol + rocuronium + remifentanil + fentanyl.